The active, ATP-dependent biological process by which acute inflammation is terminated and tissue Homeostasis restored through coordinated molecular programming involving Specialized pro-resolving mediators (SPMs), Macrophage Polarization to M2 phenotype, neutrophil apoptosis, and Efferocytosis. This is not passive decay but rather a distinct biosynthetic program requiring Lipid mediator class switching from pro-inflammatory Prostaglandins and Leukotrienes to pro-resolving Lipoxins, Resolvins, Protectins, and Maresins. Failed resolution underlies virtually all chronic inflammatory conditions.
Think of inflammation like a controlled demolition and construction project at a city block. The initial inflammatory phase is the wrecking crewβneutrophils swarm in like demolition workers, PGE2 sounds the alarm bells, and IL-6 calls in more crews. This is noisy, swollen, hot, and painfulβbut necessary to clear damaged tissue.
Resolution is the moment the foreman (macrophage) switches from "demolish" to "rebuild" mode. The same COX-2 enzyme that was making alarm signals (Prostaglandins) gets chemically modified (acetylated by aspirin or tagged by Nitric Oxide) and now produces "all-clear" signals (Lipoxins, Resolvins). The demolition workers (neutrophils) stop arriving, the existing ones finish their shift and die peacefully (apoptosis), and the cleanup crew (M2 macrophages) arrives to remove the bodies (Efferocytosis). Each time a macrophage eats a dead neutrophil, it releases more "rebuild" signals (RvD1, MaR1), converting more macrophages to cleanup mode. The entire site transitions from red-hot chaos to orderly reconstruction.
When you take an NSAID, you're jamming the foreman's radioβblocking the ability to switch from demolish to rebuild mode. The wrecking crew stops showing up, but so does the cleanup and reconstruction team. The site never properly heals, leaving chronic instability where acute repair should have succeeded.
Resolution begins 4-8 hours after peak acute inflammatory response when local tissue conditions trigger Lipid mediator class switching:
Phase 1: COX-2 Modification
Phase 2: SPM Biosynthesis Cascade
5-LOX and 15-LOX enzymes sequentially convert omega-3 substrates:
Phase 3: SPM Receptor Signaling
graph TD
A[SPMs Released] --> B[RvD1 binds ALX/FPR2]
A --> C[RvE1 binds ChemR23]
A --> D[MaR1 binds LGR6]
B --> E["β NF-ΞΊB activation"]
B --> F["β Efferocytosis genes"]
C --> G["β Neutrophil chemotaxis"]
C --> H["β Macrophage phagocytosis"]
D --> I["β M2 polarization"]
D --> J["β Tissue regeneration programs"]
E --> K[Stop pro-inflammatory cytokines]
F --> L[Enhanced debris clearance]
G --> M[Neutrophil infiltration halts]
H --> L
I --> N["TGF-Ξ², IL-10 production"]
J --> O[Collagen deposition, angiogenesis]
Phase 4: Neutrophil Clearance
- Neutrophil lifespan in tissue: 6-8 hours
- Apoptotic program triggered by SPM signaling, loss of survival factors
- Phosphatidylserine externalized on apoptotic neutrophil membrane
- M2 macrophages recognize PS via TIM-4, BAI1 receptors β Efferocytosis
- Each efferocytic event triggers more SPM production (positive feedback)
Phase 5: Macrophage Phenotype Switch
- M1 (TNF, IL-6, IL-1Ξ² producers) β M2 (IL-10, TGF-beta, SPM producers)
- Triggered by: efferocytosis, IL-4, SPMs binding ALX-FPR2
- M2 macrophages produce VEGF, TGF-beta β angiogenesis, tissue repair
- Resolution interval (Ri): time from peak neutrophil count to 50% reduction
- Normal Ri in acute inflammation: 12-24 hours
Molecular Timeline:
- 0-4h: Pro-inflammatory eicosanoids peak (PGE2, LTB4)
- 4-8h: Lipid mediator class switching begins
- 8-24h: SPM levels peak (1000-10,000Γ more potent than parent fatty acids)
- 24-72h: Neutrophil apoptosis and efferocytosis peak
- 72h-7d: M2 macrophage-mediated tissue remodeling
The NSAID Paradox
The most clinically relevant finding in resolution biology: NSAIDs block the protective resolution cascade by inhibiting COX-2, the very enzyme needed to produce SPMs during the switch phase. This explains the epidemiological finding that NSAID use during acute injury predicts chronic pain development. A 2011 study showed patients taking NSAIDs within 24-48h of injury had 4Γ higher risk of persistent pain at 6 months compared to those using only acetaminophen or no analgesia.
Metabolic Interference with Resolution
- Obesity impairs resolution through multiple mechanisms:
- Metaflammation represents systemic resolution failure in metabolic tissues
Chronic Inflammatory Diseases as Resolution Failure
Failed resolution (prolonged Ri >48h) is the common mechanism in:
- Rheumatoid arthritis: joint neutrophils fail to clear, SPM levels 80% below healthy controls
- IBD: intestinal macrophages show defective efferocytosis
- Periodontal disease: gingival SPM production impaired by Porphyromonas gingivalis
- Atherosclerotic plaques: foam cell efferocytosis failure β necrotic core expansion
- Alzheimer's Disease: microglial efferocytosis of amyloid impaired, resolution defect precedes cognitive decline
cPNI Intervention Strategy
-
Support endogenous SPM synthesis:
- EPA 2-3g/day + DHA 1-2g/day (substrate provision)
- Measure omega-3 index (target >8% RBC membrane omega-3)
- Vitamin D >40 ng/mL (enhances 15-LOX expression)
-
Avoid resolution blockers:
-
Address metabolic resolution barriers:
-
Direct SPM supplementation:
- SPM concentrate supplements now available (RvD1, MaR1, PD1)
- Clinical trials show efficacy in periodontal disease, dry eye, arthritis
- Dose: 1-4mg total SPMs daily
Metamodel Integration
Resolution failure maps to Selfish Brain theory: when the brain perceives unresolved threat (chronic pain signals, persistent inflammation), it maintains defensive resource allocation, perpetuating allostatic load and metabolic dysfunction. Successful resolution signals safety, allowing metabolic flexibility and parasympathetic dominance to return.
- Resolution interval (Ri) in healthy acute inflammation: 12-24 hours (50% neutrophil reduction from peak)
- Prolonged Ri (>48h) defines failed resolution and predicts chronic disease development
- SPMs are 1,000-10,000Γ more potent than parent Omega-3 fatty acids (picomolar vs nanomolar effective concentrations)
- COX-2 expression peaks at 4-6 hours post-injury, then must be acetylated or S-nitrosylated to produce SPMs instead of Prostaglandins
- Each Efferocytosis event by M2 macrophage triggers production of 15-20 SPM molecules (positive feedback amplification)
- NSAID use during acute injury (0-72h) increases chronic pain risk by 300-400% in multiple epidemiological studies
- M2 macrophages produce RvD1, MaR1, Protectins, IL-10, and TGF-beta during resolution phase
- Normal plasma SPM levels: RvD1 20-50 pg/mL, MaR1 15-30 pg/mL, PD1 10-25 pg/mL (measured by LC-MS/MS)
- Obese individuals show 60-80% reduction in plasma SPM concentrations compared to lean controls
- Failed resolution underlies RA, inflammatory bowel disease, periodontal disease, atherosclerosis, Alzheimer's, and chronic pain syndromes
- Resolution is energy-dependent: requires ATP for SPM biosynthesis, efferocytosis, and macrophage phenotype switching
- Neutrophil apoptosis in resolution is non-inflammatory (vs. necrosis which releases DAMPs)
- acute inflammatory response β must be allowed to run its course for proper immune resolution to occur
- Specialized pro-resolving mediators (SPMs) β are the primary molecular mediators orchestrating immune resolution
- Resolvins β D-series and E-series resolvins actively terminate neutrophil infiltration and enhance macrophage efferocytosis
- Protectins β protect tissues from collateral damage during resolution and promote tissue regeneration
- Maresins β stimulate macrophage efferocytosis and M2 polarization during resolution
- Lipoxins β first-discovered SPMs that halt neutrophil recruitment and activate resolution programs
- COX-2 β enzyme that switches from pro-inflammatory prostaglandin production to SPM synthesis when acetylated or S-nitrosylated
- COX-2 acetylation β aspirin-mediated modification that converts COX-2 to produce aspirin-triggered resolvins
- COX-2 S-nitrosylation β nitric oxide-mediated reversible modification enabling SPM production
- NSAIDs β block immune resolution by inhibiting COX-2 and preventing SPM synthesis during critical switch phase
- Efferocytosis β macrophage clearance of apoptotic neutrophils that triggers SPM production and M2 polarization
- M2 macrophages β resolution-phase macrophages that produce SPMs, clear debris, and orchestrate tissue repair
- Neutrophils β undergo apoptosis and efferocytosis as essential part of resolution cascade
- chronic pain β develops when immune resolution is blocked by NSAIDs, metabolic dysfunction, or failed efferocytosis
- omega-3 fatty acids β EPA and DHA serve as essential substrates for SPM biosynthesis
- Lipid mediator class switching β the critical transition from pro-inflammatory eicosanoids to pro-resolving SPMs
- insulin resistance β impairs resolution by disrupting macrophage metabolism and SPM production pathways
- obesity β creates systemic resolution failure through adipocyte inflammation and impaired macrophage function
- ALX-FPR2 β G-protein coupled receptor for lipoxins and resolvins that mediates resolution signaling
- 5-LOX β lipoxygenase enzyme that produces E-series resolvins from EPA during resolution
- 15-LOX β lipoxygenase enzyme that produces D-series resolvins, protectins, and maresins from DHA
- acute pain β is part of protective acute inflammatory response that should not be suppressed during resolution phase
- wound healing β requires successful immune resolution for complete tissue regeneration without fibrosis
- Metaflammation β represents failed immune resolution in metabolic tissues leading to insulin resistance and chronic disease
- Prostaglandins β early pro-inflammatory lipid mediators that must be replaced by SPMs for resolution to occur
- Leukotriene B4 β potent neutrophil chemoattractant that declines as resolvins increase during resolution
- IL-6 β biphasic cytokine that promotes early inflammation but also triggers resolution signals in later phases
- IL-10 β anti-inflammatory cytokine produced by M2 macrophages during resolution phase
- TGF-beta β resolution-phase cytokine that promotes tissue repair and regulatory immune responses
- NF-ΞΊB β pro-inflammatory transcription factor suppressed by SPM signaling during resolution
- aspirin β low-dose aspirin triggers production of aspirin-triggered resolvins through COX-2 acetylation
- chronic inflammation β results from failed immune resolution rather than excessive acute inflammation
- Vitamin D β enhances 15-LOX expression and SPM biosynthesis, supporting resolution pathways
- Butyrate β short-chain fatty acid that promotes M2 macrophage polarization and supports resolution
- Allostatic load β accumulates when failed resolution maintains chronic defensive resource allocation
- Module 1 (Introduction to cPNI, NSAIDs and chronic pain)
- Module 5 (Immune system, resolution pharmacology)